Lineage Cell Therapeutics, Inc. (LCTX) — 8-K Filings

8-K Filings (16)

• 8-K Filing — Nov 28, 2025
• 8-K Filing — Nov 24, 2025
• Lineage Cell Therapeutics Files 8-K — Nov 12, 2025 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on November 12, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dol
• Lineage Cell Therapeutics Files 8-K — Aug 26, 2025 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on August 26, 2025, reporting on various events. The filing includes information related to financial statements an
• Lineage Cell Therapeutics Files 8-K on Corporate Governance — Jul 2, 2025 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on the departure of directors or certain officers, election of directors, appointment o
• Lineage Cell Therapeutics Files 8-K — Jun 23, 2025 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on June 23, 2025, reporting on other events and financial statements. The filing does not disclose specific new mat
• Lineage Cell Therapeutics Appoints New Auditor — Jun 9, 2025 Risk: low
  Lineage Cell Therapeutics, Inc. announced on June 3, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its ne
• Lineage Cell Therapeutics Files 8-K — May 1, 2025 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on May 1, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, bu
• Lineage Cell Therapeutics Files 8-K — Jan 27, 2025 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on January 27, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and o
• Lineage Cell Therapeutics Closes $50M Public Offering — Nov 20, 2024 Risk: medium
  Lineage Cell Therapeutics, Inc. announced on November 19, 2024, the closing of its previously announced underwritten public offering of common stock. The compan
• Lineage Cell Therapeutics Changes Accountants Amidst Disagreement — Jun 14, 2024 Risk: medium
  Lineage Cell Therapeutics, Inc. announced on June 11, 2024, a change in its principal accounting firm, with PricewaterhouseCoopers LLP resigning and BDO USA, LL
• Lineage Cell Therapeutics Files 8-K — Jun 13, 2024 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on June 13, 2024, reporting on events that occurred on June 11, 2024. The filing indicates changes to the company's
• Lineage Cell Therapeutics Files 8-K — May 14, 2024 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K on May 14, 2024, to report other events and financial statements. The filing does not contain specific financial fi
• Lineage Cell Therapeutics Closes $50M Public Offering — Mar 22, 2024 Risk: medium
  Lineage Cell Therapeutics, Inc. announced on March 12, 2024, the closing of its previously announced underwritten public offering of common stock. The company s
• Lineage Cell Therapeutics Files 'Other Events' 8-K — Feb 15, 2024 Risk: low
  Lineage Cell Therapeutics, Inc. filed an 8-K with the SEC on February 15, 2024, reporting an "Other Event" that occurred on February 14, 2024. This regulatory f
• Lineage Cell Therapeutics Files 8-K on Material Definitive Agreement — Feb 6, 2024
  Lineage Cell Therapeutics, Inc. (LCTX) filed an 8-K on February 6, 2024, to report the entry into a material definitive agreement. This filing indicates a signi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX